Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
65 巻, 15 号
選択された号の論文の27件中1~27を表示しています
REVIEW ARTICLE
ORIGINAL ARTICLES
  • Takako Takayama, Hideo Suzuki, Kazushi Maruo, Tsuyoshi Kaneko, Satoko ...
    2026 年65 巻15 号 p. 2008-2014
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2025/12/18
    ジャーナル オープンアクセス

    Objective Monitoring the condition of stool is useful for daily health management and early detection of diseases; however, a self-assessment of stool form is often inaccurate. To address this issue, TOTO, developed a prototype toilet seat equipped with a sensor that classifies stool forms according to the Bristol Stool Form Scale (BSFS). This study aimed to verify the accuracy of this method for distinguishing stool types.

    Methods We recruited 38 healthy Japanese participants and obtained BSFS data using the device from November 2021 to March 2022. Meanwhile, we taught the participants how to assess their own stool using the BSFS and used their assessments as reference standards. We evaluated the strength of agreement between the participants' assessments and the device's classification results using the kappa coefficient, as well as the strength of correlation using Spearman's rank correlation coefficient.

    Materials We analyzed 305 samples from 38 participants after excluding 62 samples for which the participant's judgment was unreliable or the device data were of a low quality.

    Results The kappa coefficient between participants' assessments and the device's classification results based on BSFS was 0.55 [95% confidence interval (CI) 0.45-0.65, p<0.001], while the Spearman's rank correlation coefficient was 0.56 (95% CI 0.48-0.63, p<0.001).

    Conclusion The device appeared to possess limited but moderate validity, with fair to good agreement and moderate correlation with the participants' assessment results. This toilet seat with an automated classification of stool form by sensing falling stool may support daily healthcare and early disease detection.

  • Takashi Kitao, Eriko Konishi, Motohiro Kubori, Yoshio Komoda, Yukiko M ...
    2026 年65 巻15 号 p. 2015-2023
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2025/12/18
    ジャーナル オープンアクセス

    Objective This study aimed to investigate the short-term effect of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on serum magnesium (sMg) across three subgroups stratified according to the severity of albuminuria in patients with type 2 diabetes mellitus (T2DM).

    Methods Ninety patients were stratified into three subgroups according to their urinary albumin-to-creatinine ratio (UACR) at the initiation of SGLT2i treatment, according to the severity classification of albuminuria: A1 (normoalbuminuria; n=39), A2 (microalbuminuria; n=30), and A3 (macroalbuminuria; n=21). We evaluated the changes in sMg three months after the initiation of SGLT2i treatment in each subgroup. Subsequently, we compared the changes (Δ) in sMg levels across the three subgroups. Additionally, we investigated the baseline parameters correlated with Δ sMg, as well as the changes in parameters associated with Δ sMg.

    Results sMg was significantly increased in all subgroups (p<0.001 for A1, A2, and A3). Δ sMg was significantly different across the three subgroups (p=0.036), and Δ sMg in A3 was significantly greater than that in A1 (p=0.032). Δ sMg was positively correlated with baseline UACR (β=0.244, p=0.040) and inversely correlated with baseline sMg (β=-0.478, p<0.001). Δ sMg was positively correlated with Δ serum albumin level (β=0.239, p=0.033).

    Conclusion The short-term effect of SGLT2is on sMg levels was more pronounced in T2DM patients with macroalbuminuria.

  • Mayuko Hori, Hiroshi Takahashi, Chika Kondo, Asami Takeda, Kunio Moroz ...
    2026 年65 巻15 号 p. 2024-2031
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2025/12/18
    ジャーナル オープンアクセス

    Objective Constipation, a clinical form of gut dysbiosis, is highly prevalent in patients undergoing hemodialysis. Patients with chronic kidney disease experience uremia-related changes in the gut environment. Dysbiosis reportedly leads to an atherosclerosis pathogenesis, and constipation is associated with several adverse clinical outcomes including cardiovascular disease and mortality. Phosphate binders, commonly prescribed to patients with end-stage renal disease, bind to non-phosphate molecules and may alter the gut microbiota, potentially leading to systemic effects unrelated to phosphate control, although the clinical evidence is limited.

    Methods This cross-sectional study included 293 outpatients undergoing hemodialysis at Masuko Memorial Hospital, Japan. Information about patient characteristics and medication usage was collected, and constipation was assessed using the original diagnostic criteria, incorporating both the Rome IV criteria and a history of laxative use.

    Results Of 293 participants, 152 (51.9%) were diagnosed with constipation and 60 (20.5%) had severe constipation. Lanthanum carbonate use was independently associated with a lower risk of constipation [adjusted odds ratio (aOR) 0.55, 95% confidence interval (CI) 0.32-0.94, p=0.029] and a lower risk of severe constipation (aOR 0.41, 95%CI 0.19-0.86; p=0.018), while precipitated calcium carbonate use was associated with a lower risk of severe constipation, independent of age and sex (aOR 0.48, 95%CI 0.26-0.89, p=0.021).

    Conclusion Our study highlights the association between specific phosphate binders and a lower risk of constipation. Accordingly, phosphate binders could be selected based on their positive effects on constipation in this patient population.

  • Junko Itano, Hisao Higo, Goro Kimura, Megumi Takemoto, Noriko Hayashib ...
    2026 年65 巻15 号 p. 2032-2044
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2025/12/11
    ジャーナル オープンアクセス
    電子付録

    Objective A quantitative computed tomography (QCT) analysis based on whole-lung density (WLD) histograms helps monitor the state of interstitial lung disease. We investigated the changes in QCT metrics in patients with drug-associated interstitial lung disease (DILD) and their correlation with inflammatory markers.

    Methods A QCT analysis using a 3D Slicer software program based on a WLD histogram was performed, excluding patients treated with anticancer agents or those undergoing treatment for malignant tumors to eliminate the effect of tumor size on QCT values. We evaluated the percentages of high attenuation areas (HAA%) at -700 Hounsfield Units (HU) (HAA%-700), -600 HU (HAA%-600), and from -600 to -250 HU [HAA%-(600-250)].

    Materials We analyzed patients diagnosed with DILD at our hospital between July 2013 and October 2024.

    Results The HAA%-700, HAA%-600, and HAA%-(600-250) values were significantly higher at diagnosis compared to the post-treatment values (28.14±13.60% versus 15.64±9.70%, p=0.0002; 18.45±10.40% versus 9.88±6.26%, p=0.0002; and 14.00±8.14% versus 7.65±4.72%, p=0.0002, respectively). The steroid-treated group had higher inflammatory marker levels than the non-steroid-treated group at the time of diagnosis. The HAA%-600 was significantly higher in the steroid-treated group than that in the non-steroid-treated group (21.42±12.35% vs. 13.18±4.31%, p=0.0128). The HAA%-700, HAA%-600, and HAA%-(600-250) values correlated with the inflammatory marker values.

    Conclusion The HAA% values in patients with DILD were significantly higher at diagnosis than after treatment and they also correlated with the inflammatory marker values.

  • Hiroya Kawasaki, Kazunori Tobino
    2026 年65 巻15 号 p. 2045-2049
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2026/01/02
    ジャーナル オープンアクセス

    Objective To determine the clinical significance of sputum Pasteurella multocida in adults with structural lung disease by operationally distinguishing infection from colonization and describing outcomes of pathogen-directed therapy.

    Methods We performed a single-center, retrospective case study. Infection was defined a priori by new or worsening lower-respiratory symptoms at the time of culture, supported by inflammatory or radiologic changes; isolation without symptoms was classified as colonization. Two pulmonologists blinded to the clinical data reviewed the chest computed tomography scans. Antibiotic selection and clinical responses within 2-4 weeks were extracted from the charts.

    Results Seven adults (five women; mean age, 67.1 years) with structural airway disease were included. Middle lobe syndrome and diffuse panbronchiolitis were predominant, while bronchiectasis was present in two patients. Five of the seven patients (71.4%) reported regular dog/cat exposure. Sputum cultures were obtained for acute symptom exacerbations in four patients and for incidental imaging abnormalities in three. Three symptomatic patients received penicillin-class therapy and all improved. One symptomatic patient improved without antibiotics. No recent animal bites or scratches were reported. No severe treatment-related adverse events were observed.

    Conclusion In elderly patients with structural airway disease, sputum P. multocida during symptomatic episodes likely represents true infection and responds to targeted narrow-spectrum therapy, whereas asymptomatic isolates may reflect colonization. These observations provide a pragmatic framework to distinguish infection from colonization, support susceptibility-aligned narrow-spectrum management, and offer small-series evidence to inform antimicrobial stewardship in structural lung diseases.

  • Tetsuro Yokokawa, Kazuto Nishiura, Joh Akama, Takatoyo Kiko, Yu Sato, ...
    2026 年65 巻15 号 p. 2050-2057
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2026/01/02
    ジャーナル オープンアクセス

    Objective The pathophysiology of right ventricular failure in patients with pulmonary hypertension has not been completely examined and monitoring strategies are lacking. The 14-3-3 protein family plays a regulatory role in cardiac fibroblasts. This study investigated whether 14-3-3 epsilon, a member of the 14-3-3 protein family, was associated with right ventricular failure.

    Methods A monocrotaline-induced pulmonary hypertension rat model was used to investigate the role of 14-3-3 epsilon in right ventricular failure. Plasma samples from patients with pulmonary hypertension were analyzed using an enzyme-linked immunosorbent assay for 14-3-3 epsilon.

    Patients Right ventricular samples from a monocrotaline-induced pulmonary hypertension rat model and plasma samples (n=83) from patients with pulmonary hypertension were used.

    Results The right ventricular 14-3-3 epsilon expression was higher in the monocrotaline group than in the control group. In patients with pulmonary hypertension, the median plasma 14-3-3 epsilon level was 95 ng/mL. Plasma 14-3-3 epsilon levels were significantly associated with tricuspid lateral annular peak systolic velocity and right ventricular fractional area changes in patients with pulmonary hypertension.

    Conclusion This is the first study to demonstrate an association between 14-3-3 epsilon and right ventricular failure. Plasma 14-3-3 epsilon level may be a useful circulating marker for evaluating right ventricular dysfunction in patients with pulmonary hypertension.

  • Yasunobu Sekiguchi, Shizuka Hamano, Kosuke Arai, Hiroki Tsutsumi, Masa ...
    2026 年65 巻15 号 p. 2058-2067
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2025/12/11
    ジャーナル オープンアクセス

    Objective This study evaluated the efficacy and safety of epcoritamab in real-world clinical practice.

    Methods Data of 19 patients who received epcoritamab at Saitama Cancer Center were retrospectively analyzed.

    Results The median follow-up duration was 5.6 months. The overall response rate (ORR) was 73.7%, with a complete response (CR) rate of 47.4%. The ORR in patients with prior exposure to bendamustine was 64.3% (CR rate, 50%), and that of bendamustine-naïve was 100% (CR rate, 40%). The ORR in patients with a bendamustine-free period of ≤6 months was 42.9% (CR rate, 28.6%), while that of patients with a bendamustine-free period of >6 months was 85.7% (CR rate, 71.4%). The median progression-free survival (PFS) and overall survival (OS) have not yet been determined, but the values prior to exposure to bendamustine were 6.6 and 7.6 months, respectively. A comparison between the prior bendamustine exposure and naïve groups showed no significant differences in the PFS and OS. In patients with lactate dehydrogenase (LDH) levels of ≤303 U/L at the start of epcoritamab, the median PFS and OS were not yet reached, while in those with LDH levels of >303 U/L, the median PFS and OS were 2.3 and 3.0 months, respectively. Treatment-emergent adverse events (TEAEs) of grade ≥3 severity occurred in 18 of the 19 patients (94.7%), and in 2 of the 19 patients (10.5%), the emergence of TEAEs necessitated treatment discontinuation. Cytomegalovirus (CMV) reactivation occurred in 11 patients (57.9%).

    Conclusion Careful attention should be paid to aggressive cases and those with CMV reactivation.

  • Yoshinobu Seki, Madoka Go, Masahiro Ieko
    2026 年65 巻15 号 p. 2068-2077
    発行日: 2026/08/01
    公開日: 2026/08/01
    [早期公開] 公開日: 2026/01/02
    ジャーナル オープンアクセス
    電子付録

    Objective Acquired hemophilia A (AHA) is a rare and often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Both the prompt diagnosis and treatment of patients with AHA are essential. Data on Japanese AHA diagnostic delay are lacking; therefore, this study aimed to determine the time to AHA diagnosis in Japan, as well as to identify factors influencing the time from presentation to diagnosis.

    Methods This web-based, prospective, observational study surveyed physicians in Japan who had diagnosed or treated patients with AHA. The time from bleeding onset to diagnosis was the primary endpoint, with diagnostic testing barriers as the secondary endpoints.

    Results Of the 322 physicians who accessed the survey, 112 were included in the study. The time from bleeding onset to referral and from referral to diagnosis was ≥8 days in 31.3% (n=35) and 23.2% (n=26) of cases, respectively. The tests most commonly conducted in-hospital were activated partial thromboplastin time (aPTT) and aPTT cross-mixing tests (85.7% and 73.2%, respectively), for which results typically took <1 day to obtain. FVIII activity and FVIII inhibitor tests were more often outsourced, and when performed in-hospital, the results took ≥2 days in over 25% of cases. Across the tests surveyed, 41.7-76.2% of physicians noted difficulty in interpreting test results as a reason for AHA diagnosis delay.

    Conclusion More efficient diagnostic procedures and enhanced physician education and awareness are needed to shorten AHA diagnosis times in Japan.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
feedback
Top